CN110354071A - 一种包载十八味党参丸的水凝胶及其制备方法 - Google Patents

一种包载十八味党参丸的水凝胶及其制备方法 Download PDF

Info

Publication number
CN110354071A
CN110354071A CN201910682957.1A CN201910682957A CN110354071A CN 110354071 A CN110354071 A CN 110354071A CN 201910682957 A CN201910682957 A CN 201910682957A CN 110354071 A CN110354071 A CN 110354071A
Authority
CN
China
Prior art keywords
chitosan
radix codonopsis
taste radix
acetic acid
polyvinyl alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910682957.1A
Other languages
English (en)
Inventor
陈星羽
王祖鑫
智伟
罗超
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Southwest Jiaotong University
Original Assignee
Southwest Jiaotong University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southwest Jiaotong University filed Critical Southwest Jiaotong University
Priority to CN201910682957.1A priority Critical patent/CN110354071A/zh
Publication of CN110354071A publication Critical patent/CN110354071A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/24Mucus; Mucous glands; Bursa; Synovial fluid; Arthral fluid; Excreta; Spinal fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/55Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/19Acanthaceae (Acanthus family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/21Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/285Aucklandia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/32Burseraceae (Frankincense family)
    • A61K36/324Boswellia, e.g. frankincense
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/32Burseraceae (Frankincense family)
    • A61K36/328Commiphora, e.g. mecca myrrh or balm of Gilead
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/34Campanulaceae (Bellflower family)
    • A61K36/344Codonopsis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/47Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482Cassia, e.g. golden shower tree
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/59Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/66Papaveraceae (Poppy family), e.g. bloodroot
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/888Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8966Fritillaria, e.g. checker lily or mission bells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/898Orchidaceae (Orchid family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)

Abstract

本发明公开了一种包载十八味党参丸的水凝胶及其制备方法,包括以下步骤:步骤1:将壳聚糖加入醋酸溶液中,完全溶解后得到壳聚糖醋酸溶液;步骤2:将PVA加入得到的壳聚糖醋酸溶液中,完全溶解后得到壳聚糖/聚乙烯醇混合溶液;步骤3:将均匀分散的十八味党参丸水溶液加入的壳聚糖/聚乙烯醇混合溶液中充分混合均匀;步骤4:将的混合溶液经冻融后即可所需聚乙烯醇/壳聚糖载十八味党参丸复合水凝胶;本发明使药物可通过扩散及材料的降解缓慢释放作用于病灶部位,维持长效释放,避免频繁给药,降低药物的副作用,提高药物的利用率、安全性和有效性;通过皮肤表面给药,从而局部或透过皮肤、黏膜的吸收发挥全身治疗作用。

Description

一种包载十八味党参丸的水凝胶及其制备方法
技术领域
本发明涉及包载药物的水凝胶的制备方法,具体涉及一种包载十八味党参丸的水凝胶及其制备方法。
背景技术
藏药十八味党参丸具有消炎止痛、愈疮疡、除黄水等功能,能迅速修复补充皮肤组织基因PS-K2 DNA的缺损。改善免疫体细胞的免疫及机体免疫,提高对病菌的识别和吞噬能力,从而建立机体的自我防护屏障,对所有的皮肤疾病都有一定的治疗效果。但是传统藏药多以丸剂服用,用量大、起效慢、生物利用度低。另外,由于丸剂特殊的制剂工艺,制成品的硬度非常高,服用极为不便。
发明内容
本发明针对现有技术存在的问题提供一种可使药物通过扩散及材料的降解缓慢释放作用于病灶部位,维持长效释放、避免频繁给药,降低药物的副作用的包载十八味党参丸的水凝胶及其制备方法。
本发明采用的技术方案是:一种包载十八味党参丸的水凝胶的制备方法,包括以下步骤:
步骤1:将壳聚糖加入醋酸溶液中,完全溶解后得到壳聚糖醋酸溶液;壳聚糖醋酸溶液中壳聚糖质量浓度为2.4%,醋酸质量浓度为1%;
步骤2:将PVA加入步骤1制备得到的壳聚糖醋酸溶液中,完全溶解后得到壳聚糖/聚乙烯醇混合溶液;其中PVA与壳聚糖醋酸溶液的质量比为7:100;
步骤3:将均匀分散的十八味党参丸水溶液加入步骤2得到的壳聚糖/聚乙烯醇混合溶液中充分混合均匀;其中十八味党参丸与壳聚糖/聚乙烯醇混合溶液的质量比为:0.1%~0.9%;
步骤4:将步骤3得到的混合溶液经冻融后即可所需聚乙烯醇/壳聚糖载十八味党参丸复合水凝胶。
进一步的,所述步骤2中PVA加入壳聚糖醋酸溶液后加热至90℃,磁力搅拌3h至完全溶解。
进一步的,所述步骤4中冻融重复3次,在-20℃条件下24h后,在室温下解冻2~4h为一次冻融。
进一步的,所述步骤3中十八味党参丸水溶液的质量浓度为5%~40%。
本发明的有益效果是:
(1)本发明为十八味党参丸的新剂型,使药物可通过扩散及材料的降解缓慢释放作用于病灶部位,维持长效释放,避免频繁给药,降低药物的副作用,提高药物的利用率、安全性和有效性;
(2)本发明通过皮肤表面给药,从而局部或透过皮肤、黏膜的吸收发挥全身治疗作用;与其他常规的给药途径相比,经皮肤给药可避免肝脏首关效应及胃肠灭活、减少血药浓度、降低毒副反应。
附图说明
图1为本发明实施例1中丁香苷浓度释放曲线示意图。
图2为本发明实施例1中没食子酸浓度释放曲线示意图。
图3为本发明实施例1中木犀草浓度释放曲线示意图。
图4为本发明实施例1中载药水凝胶的药物释放曲线示意图。
图5为本发明实施例1中载药水凝胶的细胞毒性测试结果示意图。
具体实施方式
下面结合附图和具体实施例对本发明做进一步说明。
一种包载十八味党参丸的水凝胶的制备方法,包括以下步骤:
步骤1:将壳聚糖加入醋酸溶液中,完全溶解后得到壳聚糖醋酸溶液;壳聚糖醋酸溶液中壳聚糖质量浓度为2.4%,醋酸质量浓度为1%;
步骤2:将PVA加入步骤1制备得到的壳聚糖醋酸溶液中,加热至90℃,磁力搅拌3h至完全溶解后得到壳聚糖/聚乙烯醇混合溶液;其中PVA与壳聚糖醋酸溶液的质量比为7:100;
步骤3:将均匀分散的十八味党参丸水溶液加入步骤2得到的壳聚糖/聚乙烯醇混合溶液中磁力搅拌1h后使药物均匀分散;其中十八味党参丸与壳聚糖/聚乙烯醇混合溶液的质量比为:0.1%~0.9%;
步骤4:将步骤3得到的混合溶液倒入模具中,放入-20℃冰箱中24h,室温下解冻2~4h,重复3次得到聚乙烯醇/壳聚糖载十八味党参丸复合水凝胶。
实施例1
一种包载十八味党参丸的水凝胶的制备方法,包括以下步骤:
步骤1:取10g蒸馏水于烧杯中,加入0.105g醋酸,配置成醋酸溶液;取0.025g壳聚糖,将壳聚糖加入醋酸溶液中加热搅拌至完全溶解,得到壳聚糖醋酸溶液。
步骤2:称取0.75gPVA加入步骤1制备得到的壳聚糖醋酸溶液中,加热至90℃,磁力搅拌3h至完全溶解,得到壳聚糖/聚乙烯醇混合溶液。
步骤3:称取0.05g十八味党参丸粉末于1g蒸馏水中,经超声均匀分散后,加入步骤3得到的壳聚糖/聚乙烯醇混合溶液中,磁力搅拌1h后使药物均匀分散。
步骤4:将步骤3得到的混合溶液倒入模具中,放入-20℃冰箱中24h,室温下解冻2~4h,重复3次得到聚乙烯醇/壳聚糖载十八味党参丸复合水凝胶。
实施例2
一种包载十八味党参丸的水凝胶的制备方法,包括以下步骤:
步骤1:取10g蒸馏水于烧杯中,加入0.105g醋酸,配置成醋酸溶液;取0.025g壳聚糖,将壳聚糖加入醋酸溶液中加热搅拌至完全溶解,得到壳聚糖醋酸溶液。
步骤2:称取0.75gPVA加入步骤1制备得到的壳聚糖醋酸溶液中,加热至90℃,磁力搅拌3h至完全溶解,得到壳聚糖/聚乙烯醇混合溶液。
步骤3:称取0.1g十八味党参丸粉末于1g蒸馏水中,经超声均匀分散后,加入步骤3得到的壳聚糖/聚乙烯醇混合溶液中,磁力搅拌1h后使药物均匀分散。
步骤4:将步骤3得到的混合溶液倒入模具中,放入-20℃冰箱中24h,室温下解冻2~4h,重复3次得到聚乙烯醇/壳聚糖载十八味党参丸复合水凝胶。
实施例3
一种包载十八味党参丸的水凝胶的制备方法,包括以下步骤:
步骤1:取10g蒸馏水于烧杯中,加入0.105g醋酸,配置成醋酸溶液;取0.025g壳聚糖,将壳聚糖加入醋酸溶液中加热搅拌至完全溶解,得到壳聚糖醋酸溶液。
步骤2:称取0.75gPVA加入步骤1制备得到的壳聚糖醋酸溶液中,加热至90℃,磁力搅拌3h至完全溶解,得到壳聚糖/聚乙烯醇混合溶液。
步骤3:称取0.2g十八味党参丸粉末于1g蒸馏水中,经超声均匀分散后,加入步骤3得到的壳聚糖/聚乙烯醇混合溶液中,磁力搅拌1h后使药物均匀分散。
步骤4:将步骤3得到的混合溶液倒入模具中,放入-20℃冰箱中24h,室温下解冻2~4h,重复3次得到聚乙烯醇/壳聚糖载十八味党参丸复合水凝胶。
实施例4
一种包载十八味党参丸的水凝胶的制备方法,包括以下步骤:
步骤1:取10g蒸馏水于烧杯中,加入0.105g醋酸,配置成醋酸溶液;取0.025g壳聚糖,将壳聚糖加入醋酸溶液中加热搅拌至完全溶解,得到壳聚糖醋酸溶液。
步骤2:称取0.75gPVA加入步骤1制备得到的壳聚糖醋酸溶液中,加热至90℃,磁力搅拌3h至完全溶解,得到壳聚糖/聚乙烯醇混合溶液。
步骤3:称取0.4g十八味党参丸粉末于1g蒸馏水中,经超声均匀分散后,加入步骤3得到的壳聚糖/聚乙烯醇混合溶液中,磁力搅拌1h后使药物均匀分散。
步骤4:将步骤3得到的混合溶液倒入模具中,放入-20℃冰箱中24h,室温下解冻2~4h,重复3次得到聚乙烯醇/壳聚糖载十八味党参丸复合水凝胶。
采用实施例1制备得到的聚乙烯醇/壳聚糖载十八味党参丸复合水凝胶进行丁香苷水平测定,测定条件为340nm,流动相乙腈和水,流动相比例为乙腈:水=3:7,流速1mL/min,柱温37℃,试样进样量10μL,释放曲线如图1所示。丁香苷是一种典型的酚苷类化合物,是十八味党参丸的有效成分,也是祖师麻、救必应、天女木兰、关东丁香等中药的主要成分,是药材及其制剂含量测定的指标成分之一。丁香苷对急性炎症早期的毛细血管扩张、渗出水肿有一定的抑制作用,对中晚期炎症纤维组织增生、肉芽形成有抑制作用,同时有镇痛作用。
采用实施例1制备得到的聚乙烯醇/壳聚糖载十八味党参丸复合水凝胶进行没食子酸水平测定,测定条件为270nm,流动相甲醇和0.4%磷酸,流动相比例为甲醇:0.4%磷酸=5:95,流速1mL/min,柱温37℃,试样进样量10μL,释放曲线如图2所示。没食子酸是十八味党参丸中的有效成分,具有固牙止痛、止血凉血、清热消炎、燥湿收敛、祛瘀愈伤、止泻止痢等功效。主要用于治疗牙龈出血肿痛、牙齿松动、咽喉肿痛、疮疡腐烂、伤口不愈、湿性白带过多、子宫出血、泻痢不止等疾病。
采用实施例1制备得到的聚乙烯醇/壳聚糖载十八味党参丸复合水凝胶进行木犀草素水平测定,测定条件为340nm,流动相甲醇和0.4%磷酸,流动相比例为甲醇:0.4%磷酸=5:95,流速1mL/min,柱温37℃,试样进样量10μL,释放曲线如图3所示。木犀草素是十八味党参丸的有效成分,是一种天然黄酮类化合物,具有多种药理活性,如抗炎、抗氧化、免疫调节、血管生成及神经保护作用。
采用实施例1制备得到的聚乙烯醇/壳聚糖载十八味党参丸复合水凝胶记性体外释放测定,曲线如图4所示。取1g/10mL载药水凝胶放入PBS中,分别在1h、2h、3h、4h、5h、6h、7h、8h、9h、10h、11h时取出2mL过滤后用HPLC检测其中有效成分含量,再加入2mLPBS到原溶液中,继续进行释药实验。
聚乙烯醇/壳聚糖载十八味党参丸复合水凝胶(5%载药量)能够在生理情况下有效缓释,使药物可以通过扩散及材料的降解缓慢释放作用于病灶部位,维持长效释放,避免频繁给药,提高药物的利用率、安全性和有效性,对其在人体的应用有重要意义。
图5为本发明实施例1制备得到的聚乙烯醇/壳聚糖载十八味党参丸复合水凝胶细胞毒性测试结果。按照0.1g/mL将水凝胶浸泡在培养基中24h,取浸提液作为实验组培养基。在96孔板中每个孔接种4×103个细胞,并设置对照组。通过AlamarBlue测量细胞毒性,在每个时间点,用含有10%AlamarBlue溶液的DMEM替换培养基并孵育4小时。温育后,将各孔的100μL培养基转移到96孔板中,用酶标仪记录570nm和600nm处的吸光度。从图5中可以看出聚乙烯醇/壳聚糖十八味党参丸复合水凝胶的RGR都超过75%,说明其对细胞没有毒性,有希望能够进一步应用于人体。
其中RGR计算公式如下:
表1.细胞相对增值度RGR评价
聚乙烯醇/壳聚糖十八味党参丸复合水凝胶降低了单独药物的细胞毒性,并且具有良好的细胞相容性,说明聚乙烯醇/壳聚糖载十八味党参丸复合水凝胶只改变了药物的吸收能力和对人体的毒性,并没有改变药物的固有效果,是一种有效的药物包式。
本发明中用到十八味党参丸为粉末制剂,具有消炎止痛、愈疮疡,除黄水的功能;壳聚糖为脱乙酰甲壳素,是一种天然高分子可作为食品添加剂;聚乙烯醇是一种水溶性高分子,具有耐溶剂性、柔韧性、平滑性、强力粘接性。
本发明利用壳聚糖和聚乙烯醇结合包载十八味党参丸,运用于皮肤组织的修复治疗;传统藏药多以丸剂服用,用量大、起效慢、生物利用度低、运用先进载药控释技术开发十八味党参丸的新剂型,使药物可以通过扩散以及材料的降解缓慢释放作用于病灶部位,维持长效吸收,避免频繁给药,降低药物的副作用。通过皮肤表面给药,从而通过局部或透过皮肤、黏膜的吸收发挥全身治疗作用。与其他常规的给药途径相比,经皮给药可以避免肝脏首关效应及肠胃灭活、减少血药浓度波动、降低毒副作用。能迅速修复补充皮肤组织基因PS-K2DNA的缺损,改善免疫体细胞的免疫及机体免疫,提高对病菌的识别和吞噬能力,从而建立机体的自我防护屏障,对所有的皮肤疾病都有一定的治疗效果。
本发明聚乙烯醇/壳聚糖载十八味党参丸复合水凝胶生物相容性好、无毒、无免疫原性,具有适合的生化性质、物理性质(如大小、形状)和机械性能。能够影响载体与细胞之间的相互作用,如内吞作用、循环作用、靶向作用、粘附和增殖等,从而影响药物生物活性的发挥。力学性能稳定,能够准确定位使药物局部释放到所需要的部位并且能够在时间和空间上控制药物的释放特性以对靶细胞产生最佳的诱导效应。

Claims (5)

1.一种包载十八味党参丸的水凝胶的制备方法,其特征在于,包括以下步骤:
步骤1:将壳聚糖加入醋酸溶液中,完全溶解后得到壳聚糖醋酸溶液;壳聚糖醋酸溶液中壳聚糖质量浓度为2.4%,醋酸质量浓度为1%;
步骤2:将PVA加入步骤1制备得到的壳聚糖醋酸溶液中,完全溶解后得到壳聚糖/聚乙烯醇混合溶液;其中PVA与壳聚糖醋酸溶液的质量比为7:100;
步骤3:将均匀分散的十八味党参丸水溶液加入步骤2得到的壳聚糖/聚乙烯醇混合溶液中充分混合均匀;其中十八味党参丸与壳聚糖/聚乙烯醇混合溶液的质量比为:0.1%~0.9%;
步骤4:将步骤3得到的混合溶液经冻融后即可所需聚乙烯醇/壳聚糖载十八味党参复合水凝胶。
2.根据权利要求1所述的一种包载十八味党参丸的水凝胶的制备方法,其特征在于,所述步骤2中PVA加入壳聚糖醋酸溶液后加热至90℃,磁力搅拌3h至完全溶解。
3.根据权利要求1所述的一种包载十八味党参丸的水凝胶的制备方法,其特征在于,所述步骤4中冻融重复3次,在-20℃条件下24h后,在室温下解冻2~4h为一次冻融。
4.根据权利要求1所述的一种包载十八味党参丸的水凝胶的制备方法,其特征在于,所述步骤3中十八味党参水溶液的质量浓度为5%~40%。
5.如权利要求1~4任一项制备方法得到的一种包载十八味党参丸的水凝胶。
CN201910682957.1A 2019-07-26 2019-07-26 一种包载十八味党参丸的水凝胶及其制备方法 Pending CN110354071A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910682957.1A CN110354071A (zh) 2019-07-26 2019-07-26 一种包载十八味党参丸的水凝胶及其制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910682957.1A CN110354071A (zh) 2019-07-26 2019-07-26 一种包载十八味党参丸的水凝胶及其制备方法

Publications (1)

Publication Number Publication Date
CN110354071A true CN110354071A (zh) 2019-10-22

Family

ID=68222505

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910682957.1A Pending CN110354071A (zh) 2019-07-26 2019-07-26 一种包载十八味党参丸的水凝胶及其制备方法

Country Status (1)

Country Link
CN (1) CN110354071A (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115364274A (zh) * 2022-07-14 2022-11-22 贵州中医药大学 一种血人参乙醇提取物水凝胶的制备及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105497087A (zh) * 2015-11-25 2016-04-20 牟杰 负载三七纳米氧化锌缓释凝胶及其制备方法和应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105497087A (zh) * 2015-11-25 2016-04-20 牟杰 负载三七纳米氧化锌缓释凝胶及其制备方法和应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
常美月等: "中药药用凝胶剂的研究概况", 《中国中医药现代远程教育》 *
王娜等: "聚乙烯醇/壳聚糖复合水凝胶的物理化学性质", 《中国科学: 化学》 *
谷雨龙: "《百种藏成药研究》", 31 March 2018 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115364274A (zh) * 2022-07-14 2022-11-22 贵州中医药大学 一种血人参乙醇提取物水凝胶的制备及应用

Similar Documents

Publication Publication Date Title
CN1951369A (zh) 白藜芦醇包衣纳米脂质体及其制备方法
CN104116734A (zh) 一种治疗口腔、咽喉疾病的药物组合物、药物制剂及应用和制法
CN101011481B (zh) 白花蛇舌草提取物及其药物制剂、制备方法和应用
CN110354071A (zh) 一种包载十八味党参丸的水凝胶及其制备方法
Zeng et al. Preparation, characterization, and pharmacodynamic study on deep second degree burns of total flavonoids composite phospholipids liposome gel of Oxytropis falcata Bunge
CN111297880B (zh) 一种用于抑制肿瘤增殖、迁移的双黄连配方药物
CN101049485A (zh) 桑姜感冒软胶囊及其制备方法
CN114177231B (zh) 一种退热的药物组合物、退热凝胶及制备方法
CN102836292A (zh) 五味消毒饮加味提取物对小鼠角叉菜胶炎症的研究方法
CN102579528B (zh) 一种防治前列腺疾病的药物组合物
CN107625852A (zh) 一种清热利湿化瘀止带中药组合物及其制备工艺和应用
CN108014301A (zh) 一种治疗白血病的中药酵素及其制备方法
CN105456528A (zh) 一种治疗妇科炎症的栓剂及其制备方法
CN104739995A (zh) 一种治疗盆腔炎的中药无糖颗粒
CN107198696A (zh) 车叶草苷酸在制备治疗肾纤维化药物中的应用
CN113144033A (zh) 一种抑菌温敏凝胶及其制备方法和应用
CN101940585B (zh) 一种以荭草素-2"-O-β-L-半乳糖苷为主要成分的组合物及其用途
CN114452354B (zh) 一种用于伤口的中药组合物及其提取物和应用
CN100592912C (zh) 一种治疗妇科疾病的外用复方制剂及其制备方法
CN106727768A (zh) 一种治疗子宫内膜炎的药物组合物
CN100569265C (zh) 一种糖脉康片及其制备方法
CN108310098A (zh) 一种治疗痤疮的组合药物及其制备方法
CN108030897A (zh) 一种治疗前列腺癌的中药酵素及其制备方法
CN114432235B (zh) 一种可用于注射的双功能缓释型超分子水凝胶的制备方法
CN1186052C (zh) 一种治疗盆腔炎的药物及其药物制剂和制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20191022